Business Trends– category –
-
Samsung Display Announces Mass Production of 24.5-inch FHD QD-OLED Panels Optimized for Esports at Gamescom 2026
Business Wire / Samsung Display South Korea Overview Samsung Display announced plans to mass-produce 24.5-inch FHD QD-OLED panels optimized for esports and FPS gaming by year-end, unveiled at Gamescom 2026. These displays offer an ultra-... -
The Unspoken Challenge: Cell Therapy Developers Lack Full Product Understanding at Clinical Stage
VOKA Unknown Overview A critical challenge in cell therapy development is that developers often lack a complete understanding of their products even at the point of patient administration. Participants in Cell&Gene Foundry concluded ... -
Cellipont Bioservices’ Texas Facility Propels Six Client Cell Therapy Programs to Expected 2026 IND Submissions
PR Newswire (Cellipont Bioservices) USA Overview Cellipont Bioservices, a cell therapy CDMO, announced that its Texas facility has supported six client projects anticipated to reach Investigational New Drug (IND) submission in 2026. This... -
Biotech Alliances Surge: Alteogen-Novartis Subcutaneous Drug Delivery Deal and NewBiologix-Synastra Gene Therapy Manufacturing Partnership Highlight Industry Trends
PharmExec Unknown Overview Alteogen has signed an option and license agreement with Novartis for subcutaneous drug development, while NewBiologix and Synastra announced a partnership to develop stable production cell lines for Duchenne m... -
UniQure Files for FDA Approval of Huntington’s Gene Therapy AMT-130, Pursuing Breakthrough for Neurological Disorder
BioPharma Dive USA Overview After overcoming previous regulatory challenges, UniQure has submitted its gene therapy AMT-130 for FDA approval, aiming to be the first medicine to address the underlying cause of Huntington's disease. The co... -
Ultragenyx’s Phase 3 Angelman Syndrome Trial Fails, Triggering 43% Stock Plunge
Fierce Biotech USA Overview Ultragenyx reported that its investigational asset apazunersen failed to meet primary and secondary endpoints in the Phase 3 Aspire trial for Angelman syndrome, leading to a dramatic 43% drop in the company's ... -
TScan Therapeutics Pivots to In Vivo TCR-T for Solid Tumors, Cuts 75% of Staff
BioPharm International USA Overview TScan Therapeutics announced a strategic pivot toward in vivo gene-edited TCR-T cell therapy for solid tumors, accompanied by a reduction of approximately 75% of its workforce. The company will halt it... -
Fate Therapeutics to Announce iPSC-Derived Immunocellular Therapy Strategy at 2026 Cantor Conference
GlobeNewswire USA Overview Fate Therapeutics announced its participation in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference. The company holds a leading position in creating multi-gene-edited iPSC lines and manufac... -
REPROCELL Accelerates Clinical Production with FDA/EMA/PMDA-Compliant iPSC Manufacturing Platform
REPROCELL Japan Overview REPROCELL has unveiled a robust iPSC manufacturing scale-up strategy aimed at accelerating clinical development and commercialization of iPSC-based therapeutics. Their StemRNA™ Clinical iPSC Platform offers clini... -
REPROCELL Publishes Article on Scaling iPSC Manufacturing: Addressing Challenges from Cell Line Development to Clinical Production
REPROCELL Japan Overview REPROCELL has published an article titled "Scaling iPSC Manufacturing: From Cell Line Development to Clinical Production," focusing on the crucial aspects of industrializing induced pluripotent stem cell (iPSC) t...
